In a letter to the lawyers of Pfizer (PFE) and Novo Nordisk (NVO), Federal Trade Commission director Daniel Guarnera said Novo Nordisk’s latest takeover offer for Metsera (MTSR) would violate the Hart-Scott-Rodino Premerger Notification Act if it’s consummated “without first filing for premerger review, Madison Muller and Josh Sisco of Bloomberg report. Shares of Metsera, which has received offers from both Novo and Pfizer, are down 5% to $69.85 in afternoon trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- FTC says Novo bid for Metsera raises filing concerns, Bloomberg reports
- Metsera drops 5% to $69.55 after Bloomberg report of FTC filing concerns
- M&A News: Novo Nordisk Stock (NVO) Slides after Increasing Its Metsera Offer to $10B
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV
- Metsera rises 17.7%